Price
$2.72
Decreased by -4.90%
Dollar Volume
54.14 K
ADR%
13.86
Earnings Report Date (estimate)
Mar 15, 23 (-0.25)
Market Cap.
98.31 M
Shares Float
9.79 M
Shares Outstanding
36.14 M
Beta
0.06
Price / Earnings
-2.70
BPR
59.80
20D Range
1.36 3.76
50D Range
0.87 3.76
200D Range
0.87 4.92
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 22 -0.24
Decreased by -9.09%
-0.28
Increased by +14.29%
Aug 11, 22 -0.26
Decreased by -4.00%
-0.23
Decreased by -13.04%
May 12, 22 -0.30
Decreased by -11.11%
-0.21
Decreased by -42.86%
Mar 17, 22 -0.23
Increased by +36.11%
-0.28
Increased by +17.86%
Nov 10, 21 -0.22
Increased by +29.03%
-0.26
Increased by +15.38%
Aug 12, 21 -0.25
Increased by +3.85%
-0.26
Increased by +3.85%
May 13, 21 -0.27
Increased by +44.90%
-0.32
Increased by +15.62%
Mar 18, 21 -0.36
Increased by +25.00%
-0.29
Decreased by -24.14%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-8.61 M
Decreased by -58.96%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by -100.00%
-9.21 M
Decreased by -48.77%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-8.77 M
Decreased by -59.67%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
-6.05 M
Increased by +8.71%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by -100.00%
-5.42 M
Increased by +6.07%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 1.17 M
Increased by +3.67 K%
-6.19 M
Decreased by -31.51%
Decreased by -530.31%
Increased by +96.51%
Mar 31, 21 0.00
Decreased by N/A%
-5.50 M
Decreased by -8.21%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 504.00 K
Increased by +N/A%
-6.62 M
Decreased by -44.44%
Decreased by -1.31 K%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.